Frazier Financial Advisors LLC Has $73,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

Frazier Financial Advisors LLC cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 24.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 935 shares of the company’s stock after selling 301 shares during the quarter. Frazier Financial Advisors LLC’s holdings in AstraZeneca were worth $73,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of AZN. McClarren Financial Advisors Inc. increased its holdings in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. acquired a new position in shares of AstraZeneca during the second quarter worth $26,000. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca during the third quarter worth $28,000. Pathway Financial Advisers LLC acquired a new stake in AstraZeneca in the first quarter valued at $29,000. Finally, CANADA LIFE ASSURANCE Co increased its holdings in AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of AZN opened at $63.23 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $196.05 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The firm’s fifty day simple moving average is $75.03 and its two-hundred day simple moving average is $78.22. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period last year, the business posted $0.87 EPS. As a group, analysts predict that AstraZeneca PLC will post 4.07 EPS for the current year.

Analyst Ratings Changes

AZN has been the subject of a number of recent research reports. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.